Commentary Open Access
Volume 2 | Issue 4 | DOI: https://doi.org/10.33696/immunology.2.033

Lung-targeted SERCA2a Gene Therapy: From Discovery to Therapeutic Application in Bleomycin-Induced Pulmonary Fibrosis

  • 1Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA
+ Affiliations - Affiliations

Corresponding Author

Lahouaria Hadri, Lahouaria.hadri@mssm.edu

Received Date: April 20, 2020

Accepted Date: May 06, 2020


Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by an accumulation of scar tissue within the lungs and the common presence of usual interstitial pneumonia. Unfortunately, only a few FDA-approved therapeutic options are currently available for the treatment of IPF and IPF remains associated with poor prognosis. Therefore, the identification of new pharmacological targets and strategies are critical for the treatment of IPF. This commentary aims to further discuss the role of sarcoplasmic reticulum Ca2+-ATPase 2a and its downstream signaling in IPF. Finally, this commentary offers new insights and perspectives regarding the therapeutic potential of AAV-mediated SERCA2A gene therapy as an emerging therapy for respiratory diseases.


SERCA2a; Lung Fibrosis; AAV1; Gene Therapy

Author Information X